Cardiogenic Shock Following Recombinant Alpha-2b Interferon Therapy for Chronic Hepatitis C A Case Report

Hiroki TERAGAWA; Tatsuya HONDO; Hajime AMANO; Hiroshi WATANABE; Hirotoki OHE; Nobuaki HATTORI; Yasunori WATANABE; Fumiaki HINO; Makoto OHBAYASHI

doi:10.1536/ihj.37.137

Cardiogenic Shock Following Recombinant Alpha-2b Interferon Therapy for Chronic Hepatitis C

A Case Report

Hiroki TERAGAWA, Tatsuya HONDO, Hajime AMANO, Hiroshi WATANABE, Hirotoki OHE, Nobuaki HATTORI, Yasunori WATANABE, Fumiaki HINO, Makoto OHBAYASHI

Author information

Hiroki TERAGAWA
Department of Internal Medicine, Onomichi General Hospital
Tatsuya HONDO
Department of Internal Medicine, Onomichi General Hospital
Hajime AMANO
Department of Internal Medicine, Onomichi General Hospital
Hiroshi WATANABE
Department of Internal Medicine, Onomichi General Hospital
Hirotoki OHE
Department of Internal Medicine, Onomichi General Hospital
Nobuaki HATTORI
Department of Internal Medicine, Onomichi General Hospital
Yasunori WATANABE
Department of Internal Medicine, Onomichi General Hospital
Fumiaki HINO
Department of Internal Medicine, Onomichi General Hospital
Makoto OHBAYASHI
Department of Internal Medicine, Onomichi General Hospital

Keywords: Acute myocarditis, Complete atrioventricular block, Regional wall motion abnormality, Pericardial effusion

JOURNAL FREE ACCESS

1996 Volume 37 Issue 1 Pages 137-142

DOI https://doi.org/10.1536/ihj.37.137

Details

Abstract

A 57-year-old woman with chronic hepatitis C was treated with alpha-2b interferon (IFN). Forty-five days after the initiation of IFN therapy, she developed cardiogenic shock. Acute perimyocarditis as a cause of cardiogenic shock was clinically suspected by the findings of complete atrioventricular block, regional wall motion abnormality and pericardial effusion. Since IFN therapy may induce cardiogenic shock in some patients, it is important to carefully monitor patients under treatment with IFN for abnormal cardiac signs.

Corresponding author

Register with J-STAGE for free!